142 related articles for article (PubMed ID: 9414415)
1. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
[TBL] [Abstract][Full Text] [Related]
2. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
Jayaram HN; Zhen W; Gharehbaghi K
Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells.
Jayaram HN; Gharehbaghi K; Jayaram NH; Rieser J; Krohn K; Paull KD
Biochem Biophys Res Commun; 1992 Aug; 186(3):1600-6. PubMed ID: 1354960
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase.
Gharehbaghi K; Paull KD; Kelley JA; Barchi JJ; Marquez VE; Cooney DA; Monks A; Scudiero D; Krohn K; Jayaram HN
Int J Cancer; 1994 Mar; 56(6):892-9. PubMed ID: 7907081
[TBL] [Abstract][Full Text] [Related]
6. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
[TBL] [Abstract][Full Text] [Related]
7. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
8. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside.
Damaraju VL; Visser F; Zhang J; Mowles D; Ng AM; Young JD; Jayaram HN; Cass CE
Mol Pharmacol; 2005 Jan; 67(1):273-9. PubMed ID: 15486050
[TBL] [Abstract][Full Text] [Related]
9. Studies on the mechanism of action of benzamide riboside: a novel inhibitor of IMP dehydrogenase.
Gharehbaghi K; Grünberger W; Jayaram HN
Curr Med Chem; 2002 Apr; 9(7):743-8. PubMed ID: 11966437
[TBL] [Abstract][Full Text] [Related]
10. Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells.
Grusch M; Rosenberger G; Fuhrmann G; Braun K; Titscher B; Szekeres T; Fritzer-Skekeres M; Oberhuber G; Krohn K; Hengstschlaeger M; Krupitza G; Jayaram HN
Cell Death Differ; 1999 Aug; 6(8):736-44. PubMed ID: 10467347
[TBL] [Abstract][Full Text] [Related]
11. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside.
Jäger W; Salamon A; Szekeres T
Curr Med Chem; 2002 Apr; 9(7):781-6. PubMed ID: 11966442
[TBL] [Abstract][Full Text] [Related]
13. Staurosporine enhanced benzamide riboside-induced apoptosis in human multidrug-resistant promyelocytic leukemia cells (HL-60/VCR) in vitro.
Hunáková L; Duraj J; Romanová D; Novotný L; Sedlák J; Kelley MR; Szekeres T; Jayaram HN; Chorváth B
Neoplasma; 1998; 45(4):204-9. PubMed ID: 9890662
[TBL] [Abstract][Full Text] [Related]
14. Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells.
Khanna N; Jayaram HN; Singh N
Life Sci; 2004 May; 75(2):179-90. PubMed ID: 15120570
[TBL] [Abstract][Full Text] [Related]
15. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
Jayaram HN; Cooney DA; Grusch M; Krupitza G
Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
[TBL] [Abstract][Full Text] [Related]
16. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS
Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.
Peñuelas S; Noé V; Morales R; Ciudad CJ
Med Sci Monit; 2005 Jan; 11(1):BR6-12. PubMed ID: 15614187
[TBL] [Abstract][Full Text] [Related]
18. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase.
Yalowitz JA; Jayaram HN
Curr Med Chem; 2002 Apr; 9(7):749-58. PubMed ID: 11966438
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
